SEC Form 4 · accession 0001209191-16-110139
Oncotelic Therapeutics, Inc. · OTLC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Simon Pedder
Director
Period of report
Mar 21, 2016
Accepted (ET)
Mar 23, 2016 · 8:53 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000908259
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $0.7277 | Mar 21, 2016 | A | 99,711 | A | — | Mar 21, 2022 | Common Stock | 99,711 | 99,711 | D |
Explanation of responses
- F1Dr. Pedder was awarded options to purchase shares of OXiGENE, Inc. common stock, $0.01 par value per share (the "Stock Options"), in connection with his appointment to the Board of Directors pursuant to the OXiGENE, Inc. 2015 Equity Incentive Plan and the Amended and Restated Non-Employee Director Compensation Policy.
- F2The Stock Options will vest in full on March 21, 2019, subject to Dr. Pedder's continued service on the Board of Directors as of such date.